Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Cognitive Emotional and Neural Signature
2020-005773-27Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of baricitinib in rheumatoid arthritis (RA) and Inflammatory Polyarthritis, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Accurate responses in facial emotion recognition task at day 1. Started Jan 2021; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)Inflammatory Polyarthritis
Beyond the preview
Go deeper on 2020-005773-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005773-27.